Veriheal

APRIL 11, 2022

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. You don’t take that opium poppy and ask a patient to rub it on their lip for morphine. Pennsylvania-based Groff North America is one of the companies that is getting a green light to experiment with the plant. territories.

Pharmaceutical 105

Pharmaceutical Research and Development DEA Clinical Trials 105

NORML

FEBRUARY 23, 2020

Legislation is pending, Senate Bill 165, to establish a medical marijuana access program for qualified patients with a physician’s recommendation to access medical marijuana from licensed retail outlets. Send a message to your lawmakers in support of medical marijuana access. AL resident? AZ resident? California.

Legislation 255

Legislation Patients Decriminalization Access 255

Veriheal

JULY 26, 2023

Georgia medical cannabis patients will soon have greater access to treatment as cannabis oil will be sold in many more pharmacies. Eligible patients registered with the state’s Department of Public Health can purchase cannabis oil from Georgia’s independent pharmacies.

Oil 98

Oil Patients Access THC 98

MGC Pharma

FEBRUARY 15, 2018

What will unrestricted access to Medicinal Cannabis look like in Australia? A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals Right now in Australia, access to Cannabis-based treatments is heavily restricted.

Access 100

Access Medicine Chronic Pain Research and Development 100

NORML

JANUARY 24, 2019

It seeks to redefine allowed dosage limitations and formulations, and expand patient access and reduce patient cost by adding nurse practitioners and physician assistants to the list of those authorized to issue written certifications to patients. Marijuana policy should be evidence based.

Policy 198

Policy Patients Education Legislation 198

Project CBD

NOVEMBER 11, 2023

In general, I think that botanical medicine is safer than pharmaceutical medicine, that the chances of causing harm are much less. I have many patients that want to use cannabis, and they who ask me what product should they get? I include pharmaceutical drugs in that category. Cannabis is a really special case.

Medicine 306

Medicine Research and Development Pharmaceutical Cannabis 306

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. The market for medical cannabis in Germany.

Access 105

Access Research and Development Pharmaceutical Therapy 105

NORML

JANUARY 11, 2019

Legislation is pending, Senate Bill 2134, to permit qualifying patients to cultivate personal use quantities of cannabis for therapeutic purposes. The measure would permit patients to grow up to nine cannabis plants in a locked, enclosed facility, and to possess up to three ounces of home-grown medical cannabis. ND resident?

Legislation 231

Legislation Decriminalization Hemp Patients 231

Veriheal

SEPTEMBER 7, 2022

’s medical cannabis program come on the heels of a previously enacted emergency amendment focused on senior citizens: The Medical Marijuana Patient Access Extension Emergency Amendment Act of 2022 allowed D.C. A Temporary Triumph for Medical Cannabis Patients. These changes to D.C.’s Following Aug.

Patients 98

Patients Programs Access Treatment 98

Veriheal

SEPTEMBER 16, 2020

Epidiolex is the sole cannabis-derived pharmaceutical that has been approved by the FDA – although it is worth noting that the organization has also approved three synthetic cannabis-related products. About 85% of these patients experience epilepsy as an effect of the condition, and more than half are unable to achieve seizure control.

Access 98

Access Epilepsy Treatment Conditions 98

Cannabis Law Report

AUGUST 22, 2021

. “The Janus particle solution will allow for time-released and combined therapies to be administered to patients, targeting specific indications. is using cutting-edge delivery technologies to develop safe and effective psychedelic pharmaceutical medicines. ” About Psycheceutical, Inc. Psycheceutical, Inc.

Pharmaceutical 98

Pharmaceutical Medicine Research and Development Therapy 98

NORML

FEBRUARY 1, 2019

Click here to email your lawmakers in support of banking access. Legislation is pending, House Bill 6849, to permit qualifying patients to cultivate personal use quantities of cannabis for therapeutic purposes. The measure would permit medical cannabis patients to grow up to six cannabis plants. CA resident? CT resident?

Legislation 188

Legislation Decriminalization Access Patients 188

Cannabis Law Report

JUNE 23, 2021

Valcon Medical A/S Announces Receipt of EU GMP Certification and Start of Commercial Production for Pharmaceutical-Grade Cannabis Concentrates, Intermediary Products, and Medical Formulations (PRNewsfoto/Valcon Medical A/S).

Pharmaceutical 86

Pharmaceutical Concentrates Extraction Medicine 86

CannaTech

SEPTEMBER 23, 2019

The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. Israel’s approach to cannabis has contributed to reducing stigma and increasing access for patients around the world.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Canna Law Blog

MARCH 25, 2025

Follow strict patient verification and dispensing rules. Can businesses cultivate cannabis for pharmaceutical research? Under the Therapeutic Goods Act and respective State/Territory guidelines, advertising medicinal cannabis directly to patients can violate advertising laws. Pharmacies must: Be registered in Australia.

Research and Development 88

Research and Development Medicine Compliance Compliance 88

Cannabis Law Report

JANUARY 6, 2022

An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. This blog post will explain how psilocybin patenting and other factors could make Oregon’s psilocybin program prohibitively expensive for low-income patients, and how big pharma is maneuvering to monopolize psychedelic therapy.

Access 52

Access Patients Research and Development Treatment 52

The Cannigma

MARCH 25, 2021

A United Kingdom police chief proposed a novel idea this January: Allow drug-dependent inmates access to free cannabis to help them overcome opioid addiction. This creates a situation where state detention facilities — even where cannabis is legal — do not allow inmates access to medical cannabis because it violates federal law.

Marijuana 145

Marijuana Access Law Pharmaceutical 145

The Cannigma

SEPTEMBER 21, 2021

There are cannabis users, patients, and just everyday fans who may be fans, but don’t make it a big part of their public persona. For these famous medical cannabis patients and supporters, it is something that can improve quality of life and which should be made readily available to anyone in need. 1) Patrick Stewart. It’s tricky.”.

Patients 94

Patients Research and Development Sleep Clinical Trials 94

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. RADNOR, Pa.–(BUSINESS

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

MGC Pharma

FEBRUARY 21, 2018

Armed with a well-developed agricultural sector, high environmental standards, world class pharmaceutical manufacturing standards, a like-minded government, and grassroot support for the industry, there can be no doubt that Australia is poised to become a Medical Cannabis powerhouse. It’s a climactic time for the Medical Cannabis industry.

Research and Development 100

Research and Development Pharmaceutical Medicine Patients 100

Veriheal

SEPTEMBER 27, 2021

The United Kingdom’s Multiple Sclerosis (MS) Society has taken a stand against restricted access to medical cannabis in the country. The society launched a campaign with the hashtag #ApprovedButDenied protesting the difficulty so many patients have faced attempting to obtain medical cannabis. ApprovedButDenied.

Treatment 98

Treatment Patients Access Research and Development 98

MGC Pharma

FEBRUARY 22, 2018

A recent Hawaii-based study of 2,736 patients above the age of 65 found that, after six months, 93.7% Unfortunately, the regulatory process is fraught with bottlenecks, with no more than 500 Australians having legal access to Medical Cannabis. namely Australia’s aging population.

Research and Development 100

Research and Development Pharmaceutical Chronic Pain Treatment 100

NORML

FEBRUARY 29, 2020

Legislation is pending, House Bill 268 and House Bill 528, to allow those convicted of simple marijuana possession to petition the court to restrict access to their records. Send a message to your lawmakers in support of access to edibles. Send a message to your lawmakers in opposition to arbitrary THC limits. GA resident? HI resident?

Legislation 163

Legislation Decriminalization Patients Edibles 163

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Veriheal

JUNE 29, 2021

In order to legally access other therapies including nature-based options such as psilocybin , you must gain access under a Right to Try law which requires you to have a terminal condition. The FDA refers to this program as the expanded access program on their website. A Push by Patients. Patients Are Not In This Alone.

Therapy 64

Therapy DEA Patients Clinical Trials 64

LifeCannMD

MARCH 3, 2025

Today, she maintains a discreet, effective regimen that has reduced her pharmaceutical intake by over half. Elena’s story sound like many of our Miami patients who find that medical marijuana edibles offer relief that helps them on a medical and personal level.

Edibles 52

Edibles Marijuana Dispensary Patients 52

Veriheal

JUNE 22, 2021

Sue Sisley was quoted telling media, “there are thousands of different cannabis varieties that all have unique chemical profiles and produce unique clinical effects, but we didn’t have access to that normal diversity.” Another company that will be cultivating cannabis for research is a pharmaceutical research company.

DEA 66

DEA Access Therapy Cannabinoids 66

LifeCannMD

JANUARY 31, 2025

#image_title At LifeCannMD, our double board-certified doctor, Dr. Fernando Fandio-Sende has had countless conversations with patients with autoimmune conditions. Dr. Sende offers Medical Marijuana recommendations for patients with one of Floridas qualifying conditions. We often hear from patients who say, “Dr.

Conditions 97

Conditions Research and Development Treatment Patients 97

Cannabis Law Report

NOVEMBER 17, 2021

This was in response to a question on Malaysia’s view of cannabis alternatives for patients raised by Muar MP Syed Saddiq Syed Abdul Rahman. The National Pharmaceutical Regulatory agency (NPRA) approved Sativex in 2014 for patients experiencing muscle spasms and spasticity from multiple sclerosis. Sativex in Malaysia.

Research and Development 111

Research and Development Patients Treatment Pharmaceutical 111

MJ Business Attorneys

JUNE 29, 2018

Epidiolex is the first drug the FDA has approved that contains a substance derived from marijuana, and it is also the first drug approved by the FDA to be used to treat patients with Dravet syndrome.

DEA 113

DEA CBD Pharmaceutical Research and Development 113

Cannabis Law Report

AUGUST 9, 2021

Currently, the common methods of use for medical cannabis are by inhalation of smoke or vapor, or sublingual drops, and many patients are reluctant to use cannabis due to these methods. The patent approval is significant for the medical cannabis market. Of Cannassure.

Cannabinoids 98

Cannabinoids Pharmaceutical Treatment Patients 98

Project CBD

MAY 3, 2023

Dr. Goldstein has treated thousands of patients with medical cannabis. Remember, the pharmaceutical model is “this medicine addresses this specific target.” There are pharmaceuticals for ADHD or behavioral issues, for example, which target this receptor. I have used it in some of my patients with autism.

Cannabinoids 213

Cannabinoids Sleep Clinical Trials CBD 213

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Accessed July 25, 2021. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Veriheal

OCTOBER 13, 2020

Elevated levels of stress can even land these individuals in more discomfort, with IBD patients risking hospitalization due to inflammation. Factors such as diet and stress are known to aggravate IBD patients, but they do not cause it. . What is IBS? What is the Difference Between IBD and IBS?

Digestion 124

Digestion Treatment Conditions Research and Development 124

MMJ Recs

AUGUST 1, 2024

While antiretroviral therapy (ART) has transformed HIV/AIDS from a fatal diagnosis to a manageable chronic condition, patients often endure chronic pain, nausea, appetite loss, and psychological distress. Medical marijuana for HIV/AIDS offers a promising complementary treatment for patients.

Patients 52

Patients Chronic Pain Marijuana Sleep 52

Cannabis Law Report

DECEMBER 15, 2021

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC ) has entered into an agreement to divest its subsidiary business, C³ Cannabinoid Compound Company GmbH (“C3”), to Dermapharm Holding SE (“Dermapharm”) (WKN: A2GS5D, ISIN: DE000A2GS5D8), a European pharmaceutical company headquartered in Grünwald, Germany.

Pharmaceutical 52

Pharmaceutical Cannabinoids Business Extraction 52